About Linkster Therapeutics

Linkster Therapeutics develops multi-specific antibodies using its Flycode® platform to enable tissue-specific delivery and enhance pharmacology profiling. This approach addresses the inefficiencies in translating in vitro antibody candidates to effective in vivo therapies, reducing off-target effects and improving treatment efficacy for serious diseases.

```xml <problem> Developing effective antibody therapies is challenging because promising in vitro candidates often fail to translate into successful in vivo treatments. This is due to issues such as poor target-organ accumulation and unexpected enrichment in off-target organs, leading to reduced efficacy and potential toxicity. Traditional antibody development methods lack efficient in vivo profiling capabilities early in the discovery process. </problem> <solution> Linkster Therapeutics addresses the translational bottleneck in antibody development with its Flycode® platform, enabling comprehensive in vivo pharmacology profiling. The platform profiles large pools of peptide-barcoded antibodies in vitro, in vivo, and in silico to identify candidates with improved tissue-specific delivery and reduced off-target effects. By integrating advanced targeting strategies and conformation-specific antibody generation, Linkster accelerates the development of precision medicines with enhanced efficacy, better dosing windows, and reduced toxicity. This approach allows for the creation of next-generation antibody drugs tailored to the right target, tissue, and patient. </solution> <features> - Flycode® platform for high-throughput in vivo pharmacology profiling of antibody candidates - Peptide-barcoded antibodies for comprehensive assessment of target-organ accumulation and off-target effects - Advanced targeting strategies for tissue-specific antibody delivery - Conformation-specific antibody generation against cell surface targets such as GPCRs and SLC transporters - Translational antibody engineering to optimize efficacy, dosing, and toxicity profiles - Sybody® platform for generating novel antibody formats </features> <target_audience> Linkster Therapeutics primarily targets pharmaceutical companies and research institutions involved in antibody drug discovery and development, seeking to improve the translational success rate of their therapeutic candidates. </target_audience> ```

What does Linkster Therapeutics do?

Where is Linkster Therapeutics located?

Linkster Therapeutics is based in Zürich, Switzerland.

When was Linkster Therapeutics founded?

Linkster Therapeutics was founded in 2019.

Location

Zürich, Switzerland

Founded

2019

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Linkster Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

linkstertx.com 1K+

Founded 2019 – Zürich, Switzerland

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Developing effective antibody therapies is challenging because promising in vitro candidates often fail to translate into successful in vivo treatments. This is due to issues such as poor target-organ accumulation and unexpected enrichment in off-target organs, leading to reduced efficacy and potential toxicity. Traditional antibody development methods lack efficient in vivo profiling capabilities early in the discovery process.

Solution

Linkster Therapeutics addresses the translational bottleneck in antibody development with its Flycode® platform, enabling comprehensive in vivo pharmacology profiling. The platform profiles large pools of peptide-barcoded antibodies in vitro, in vivo, and in silico to identify candidates with improved tissue-specific delivery and reduced off-target effects. By integrating advanced targeting strategies and conformation-specific antibody generation, Linkster accelerates the development of precision medicines with enhanced efficacy, better dosing windows, and reduced toxicity. This approach allows for the creation of next-generation antibody drugs tailored to the right target, tissue, and patient.

Features

Flycode® platform for high-throughput in vivo pharmacology profiling of antibody candidates

Peptide-barcoded antibodies for comprehensive assessment of target-organ accumulation and off-target effects

Advanced targeting strategies for tissue-specific antibody delivery

Conformation-specific antibody generation against cell surface targets such as GPCRs and SLC transporters

Translational antibody engineering to optimize efficacy, dosing, and toxicity profiles

Sybody® platform for generating novel antibody formats

Target Audience

Linkster Therapeutics primarily targets pharmaceutical companies and research institutions involved in antibody drug discovery and development, seeking to improve the translational success rate of their therapeutic candidates.